Go to Health Care Provider version
| Diagnosis | Low Grade Glioma | Study Status | Closed to enrollment |
| Phase | II |
| Age | Child, Adult - (6 Months to 18 Years) | Randomisation | YES |
| Line of treatment | First line treatment, Disease relapse or progression |
| Routes of Treatment Administration | intravenous |
| Last Posted Update | 2024-01-08 |
| ClinicalTrials.gov # | NCT02840409 |
International Sponsor
The Hospital for Sick Children / Hoffmann-La RochePrincipal Investigators for Canadian Sites
Montreal Children’s Hospital – Dr. Geneviève Legault
The Hospital for Sick Children – Dr. Uri Tabori
Alberta Children’s – Dr. Lucie Lafay-Cousin
BC Children’s Hospital – Dr. Juliette Hukin
CHU Ste-Justine – Dr. Yvan Samson
Stollery Children’s Hospital – Dr. Bev Wilson
CHU de Quebec - Dr. Valerie Larouche
CancerCare Manitoba - Dr. Issai Vanan
Children’s Hospital of Eastern Ontario (CHEO) - Dr. Donna L. Johnston
Hamilton Health Sciences Centre - Dr. Uma AthaleCentres
Medical contact
Dr. Victor Lewis
Social worker/patient navigator contact
Wendy Pelletier
Clinical research contact
Debra Rich
Medical contact
Dr. Sarah McKillop
Dr. Sunil Desai
Social worker/patient navigator contact
Danielle Sikora
Michelle Woytiuk
Jaime Hobbs
Clinical research contact
Amanda Perreault
Medical contact
Rebecca Deyell
Social worker/patient navigator contact
Ilana Katz
Clinical research contact
Hem/Onc/BMT Clinical Trials Unit
Medical contact
Dr. Magimairajan Vanan
Social worker/patient navigator contact
Rhéanne Bisson
Clinical research contact
Rebekah Hiebert
Megan Ridler
Kathy Hjalmarsson
Medical contact
Clinical Research Unit
Social worker/patient navigator contact
Clinical Research Unit
Clinical research contact
Stephanie Badour
Medical contact
Raoul Santiago
Social worker/patient navigator contact
Isabelle Audet
Clinical research contact
Barbara Desbiens
Medical contact
Dr. Henrique Bittencourt
Dr. Monia Marzouki
Dr. Sebastien Perreault (neuro-onc)
Social worker/patient navigator contact
Marie-Claude Charrette
Clinical research contact
Marie Saint-Jacques
Medical contact
Dr. Donna Johnston
Dr. Lesleigh Abbott
Dr. Doaa Abdel Fattah
Social worker/patient navigator contact
Sherley Telisma
Clinical research contact
Carol Duchenne
Medical contact
Dr. Carol Portwine
Social worker/patient navigator contact
Jane Cassano
Clinical research contact
Sabrina Millson
Study Description
This study is trying to determine the benefit of adding bevacizumab (an intravenous drug) to chemotherapy treatment with vinblastine, in children and adolescents with low grade gliomas.
Participants in this trial will be randomised (randomly assigned) into one of two treatment arms.
- Arm A will include 68 weeks (16 months) of single agent Vinblastine given once weekly intravenously.
- Arm B will include 68 weeks (16 months) of Vinblastine given weekly intravenously with the addition of 12 doses of bevacizumab given every two weeks intravenously for the initial 24 weeks (6 months).
Inclusion Criteria
- Children and adolescents aged 6 months to < 18 years
- Low grade glioma
- The tumour must have grown back after surgery with clear imaging or clinical signs, or
- The tumour was partially removed with surgery and there is a necessity to begin treatment because of a risk of neurological impairment with progression.
- Multiple other inclusion and exclusion criteria could apply and will be reviewed by your treating team
